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ABSTRACT
Objective: A comprehensive systematic review of
economic evaluations of complementary and integrative
medicine (CIM) to establish the value of these
therapies to health reform efforts.
Data sources: PubMed, CINAHL, AMED, PsychInfo,
Web of Science and EMBASE were searched from
inception through 2010. In addition, bibliographies of
found articles and reviews were searched, and key
researchers were contacted.
Eligibility criteria for selecting studies: Studies
of CIM were identified using criteria based on those of
the Cochrane complementary and alternative medicine
group. All studies of CIM reporting economic
outcomes were included.
Study appraisal methods: All recent (and likely
most cost-relevant) full economic evaluations
published 2001–2010 were subjected to several
measures of quality. Detailed results of higher-quality
studies are reported.
Results: A total of 338 economic evaluations of CIM
were identified, of which 204, covering a wide variety
of CIM for different populations, were published
2001–2010. A total of 114 of these were full economic
evaluations. And 90% of these articles covered studies
of single CIM therapies and only one compared usual
care to usual care plus access to multiple licensed CIM
practitioners. Of the recent full evaluations, 31 (27%)
met five study-quality criteria, and 22 of these also met
the minimum criterion for study transferability
(‘generalisability’). Of the 56 comparisons made in the
higher-quality studies, 16 (29%) show a health
improvement with cost savings for the CIM therapy
versus usual care. Study quality of the cost-utility
analyses (CUAs) of CIM was generally comparable
to that seen in CUAs across all medicine according to
several measures, and the quality of the cost-saving
studies was slightly, but not significantly, lower
than those showing cost increases (85% vs 88%,
p=0.460).
Conclusions: This comprehensive review identified
many CIM economic evaluations missed by previous
reviews and emerging evidence of cost-effectiveness
and possible cost savings in at least a few clinical
populations. Recommendations are made for future
studies.
INTRODUCTION
Between 1990 and 2007, four nationally
representative surveys demonstrated that a
third or more of US adults routinely used
ARTICLE SUMMARY
Article focus
▪ Given the limited nature of previous systematic
reviews, what is the extent of evidence on the
economic impacts of complementary and inte-
grative medicine (CIM)?
▪ What are the range of therapies and populations
studied, and the quality of published economic
evaluations of CIM?
▪ What are the results of the higher-quality, more
recent (and likely most cost-relevant) economic
evaluations of CIM?
Key messages
▪ This study’s comprehensive search strategy iden-
tified 338 economic evaluations of CIM, includ-
ing 114 full evaluations published 2001–2010.
▪ The cost-utility analyses found were of similar or
better quality to those published across all medicine.
▪ The higher-quality studies indicate potential cost-
effectiveness, and even cost savings across a
number of CIM therapies and populations.
Strengths and limitations of this study
▪ The strengths of this study are the comprehen-
sive search strategy, the use of two reviewers,
the use of multiple measures of study quality
and the identification of higher-quality studies,
for which results are reported in detail, via an
objective short-list of quality criteria, which
reduced the potential for bias.
▪ The weaknesses of this study are similar to
those of the other systematic reviews: reviewers
were not blinded to journals and article authors,
and some aspects of what makes a quality eco-
nomic evaluation could not be judged from what
was reported.
▪ Publication bias was not assessed. However, it is
not clear as to whether publication bias is rele-
vant, given the purposes of this review.
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Open Access Researchcomplementary and alternative medicine (CAM) therap-
ies to treat their principal medical conditions.
1–4 Total
expenditures for CAM therapies were estimated at US
$14 billion in 1990,
1 US$27 billion in 1997
2 and US$34
billion in 2007.
4 The 2007 US National Health Inventory
Survey found that out-of-pocket expenditures for CAM
therapies accounted for 11% of all out-of-pocket health-
care expenditures by Americans.
4 Similar use numbers
are seen in other countries.
5–8 However, despite the
popularity of and substantial expenditures on CAM ther-
apies, their cost-effectiveness remains ill-deﬁned and
controversial.
Economic evaluations allow costs to be included,
alongside data on safety and effectiveness, in healthcare
policy decisions. As healthcare costs rise, the availability
of these economic evaluations becomes increasingly
important to the formulation of disease management
strategies which are both clinically effective and ﬁnan-
cially responsible. According to the National Center for
Complementary and Alternative Medicine (NCCAM),
CAM is ‘a group of diverse medical and healthcare
systems, practices and products that are not generally
considered part of conventional medicine’.
9 In not
being part of conventional medicine, individual comple-
mentary therapies and emerging models of integrative
medicine (ie, coordinated access to both conventional
and complementary care)—collectively termed as com-
plementary and integrative medicine (CIM)—are often
excluded in ﬁnancial mechanisms commonly available
for conventional medicine,
2 and are rarely included in
the range of options considered in the formation of
healthcare policy. The availability of economic data
could improve the consideration and appropriate inclu-
sion of CIM in strategies to lower overall healthcare
costs. In addition, economic outcomes are relevant to
the licensure and scope of practice of practitioners,
industry investment decisions (eg, the business case for
integrative medicine), consumers and future research
efforts (ie, through identifying decision-critical para-
meters for additional research
10).
A number of systematic reviews of economic evalua-
tions of CIM have been published.
11–23 Five of these
prior reviews attempted to capture all economic evalua-
tions of CIM therapies across all conditions.
11 19–21 23
However, it is unclear as to whether all or even the
majority of economic evaluations of CIM have been
identiﬁed by these reviews. The searches are dated; the
search strategy in the most recent review only captured
articles published through 2007.
23 The databases
searched were limited—for example, only one used
CINAHL,
21 and only two others used EMBASE,
19 23 in
addition to Medline and AMED. Finally, these reviews
generally used limited search terms to identify CIM
studies. All but one only used variations on the terms
‘complementary’ or ‘alternative’‘ medicine’ or ‘therapy’.
Unfortunately, other reviewers have found that these
search terms do not capture all CIM studies,
24 25 which
may be a reﬂection of the difﬁculty in deﬁning what is
and is not CIM.
26 The search by Maxion-Bergemann
et al
11 also added individual therapies as search terms,
but only included homeopathy, phytotherapy, traditional
Chinese medicine, anthroposophic medicine and neural
therapy. No search included ‘integrative medicine’.
The goal of this paper is to identify, to the extent pos-
sible, all published economic evaluations of CIM,
describe the types of CIM evaluated and the clinical con-
ditions for which they have been evaluated, and identify
the recent (and therefore, most cost-relevant) higher-
quality studies and highlight their results for policy
makers. We also make recommendations for future eco-
nomic evaluations of CIM.
METHODS
Six electronic databases were searched from their incep-
tion through December 2010: PubMed, CINAHL,
AMED, PsychInfo, Web of Science and EMBASE. To be
as comprehensive as possible, a combination of 11
medical subject headings (MeSH) and 39 other search
terms were used (box 1). In addition, bibliographies of
found articles and reviews were searched, and key
researchers in various areas of CIM were contacted for
their lists of known studies. Although non-English lan-
guage articles were collected, they are not analysed in
this review.
Deﬁning a comprehensive search strategy for CIM is
challenging.
24 27–29 There have been a number of efforts
to develop a concise deﬁnition of CAM.
26 30 This review
used the one developed by the members of the
Cochrane CAM Field
31 and then added the terms ‘inte-
grative’, ‘integrated’ and ‘collaborative’ medicine. The
Cochrane CAM deﬁnition starts with the NCCAM deﬁn-
ition
9 and then reﬁnes it by speciﬁcally including all
Box 1
Search terms used for the PubMed search: (Complementary
Therapies (medical subject headings (MeSH)), Dietary Supplements
(MeSH), Micronutrients (MeSH), Trace Elements (MeSH), Vitamins
(MeSH), acupuncture, alternative medicine, ayurvedic medicine,
chiropractic, biofeedback, collaborative medicine, complementary
and alternative medicine, botanical medicine, complementary medi-
cine, diet, energy medicine, herbal medicine, herbs, homeopathy,
hypnosis, integrated medicine, integrative medicine, massage,
meditation, mind-body medicine, minerals, naturopathic medicine,
naturopathy, nutrients, nutritional supplements, relaxation, spa
therapy, traditional Chinese medicine OR vitamins) AND (Cost-
Benefit Analysis (MeSH), Cost Control (MeSH), Cost Savings
(MeSH), Costs and Cost Analysis (MeSH), Economics (MeSH), eco-
nomics (Subheading), Insurance (MeSH), cost benefit, cost effect-
iveness, cost identification, cost minimisation, cost utility, economic
evaluation, insurance claims, managed care OR technology assess-
ment). Searches in the other five databases used the same text
words and (where available) analogous controlled vocabulary terms.
All searches were restricted to human studies.
2 Herman PM, Poindexter BL, Witt CM, et al. BMJ Open 2012;2:e001046. doi:10.1136/bmjopen-2012-001046
Economics of complementary and integrative medicinetherapies ‘based upon the theories of a medical system
outside the Western allopathic medical model’ (eg, trad-
itional Chinese medicine and Reiki), and including
others depending on the context and setting of their
use. The context of use considers treatment/condition
combinations and excludes those ‘currently considered
to be standard treatment’, and the setting of use gener-
ally includes self-care and therapies delivered by CIM
providers, but excludes therapies ‘delivered exclusively
by conventionally credentialed medical personnel or
exclusively within hospital settings’. Therefore, therap-
ies such as chemotherapy regimens (eg, chronother-
apy
32), and therapies requiring surgical implantation
(eg, neuroreﬂexotherapy
33) or the placement of a
feeding tube
34 were not included even though these
therapies appeared in our search. In cases where CIM
therapies (eg, biofeedback or hypnosis) were included
as part of a package of care (eg, with cognitive behav-
ioural therapy), a judgement was made as to whether
the CIM portion of the treatment made up half or
more of the overall package of care under study. If so,
the package of care was included as CIM. Because
more than half of CIM users use multiple CIM therap-
ies,
35 studies of packages of therapies and coordinated
care were identiﬁed as such.
Articles were categorised as full economic evaluations
if they compared the costs (inputs) and consequences
(economic, clinical and/or humanistic outcomes
36)o f
two or more therapeutic alternatives applied to the same
patient population (ref.
37, p. 11). Otherwise, they were
considered partial evaluations, for example, cost-
identiﬁcation or cost-comparison studies.
38 Studies that
estimated resource utilisation were included as eco-
nomic evaluations if the utilisation data were detailed
enough to allow monetary valuation.
Two reviewers (PMH and BLP) evaluated all articles
for inclusion and extracted all data. Disagreements were
resolved by discussion between the two review authors,
or, if needed, by the other coauthors. Because the
results of economic evaluations can rapidly lose rele-
vance with time, mainly due to changes in practice pat-
terns and cost structures, data were extracted only from
the economic evaluations published 2001–2010.
Extracted data were entered into an Excel template
developed for a previous review.
20 The type(s) of CIM
evaluated and the target population were captured for
all economic evaluations. Various indicators of study
quality were captured for all full economic evaluations,
and more detailed data and results were captured only
for those full economic evaluations that met ﬁve quality
criteria.
The quality of an economic evaluation can be judged
along two general dimensions: (1) whether the study was
a quality measure of outcomes for its target population
and location—that is, whether it was internally valid; and
(2) whether enough information is provided for the
study’s results to be transferable (‘generalisable’).
39
Health outcomes are to some extent considered
generalisable across settings; however, because resource
availability, practice patterns and relative prices can vary
greatly, economic outcomes usually are not.
40 Therefore,
one goal in economic evaluation is to ensure the transfer-
ability of study results—that is, to provide enough study
detail so that results can be adapted (usually via model-
ling) to apply to other settings.
39 The 35-item BMJ check-
list captures components of both dimensions of quality
and was applied to all full economic evaluations.
41 We
also chose ﬁve quality criteria by which to identify a
subset of full economic evaluations to highlight as being
of most interest to policy makers. These quality criteria
are based on recommendations made by the US Panel on
Cost Effectiveness in Health and Medicine
42 and by well-
known experts in the ﬁeld,
37 and focus on the quality of
the underlying study (the ﬁrst type of quality):
▸ Because cost-effectiveness analysis (CEA) is compara-
tive, to ensure that results are useful to decision
makers, one of the alternatives to which the CIM
intervention was compared must be some version of
commonly available (routine, standard or usual) care.
▸ The analysis must explicitly or implicitly use (and
include all relevant costs from) at least one recog-
nised perspective—for example, society, third-party
payer, hospital or employer.
▸ Since ‘an economic evaluation of a healthcare pro-
gramme is only as good as the effectiveness data it is
built upon’ (ref.
43, p. 232), health outcomes must be
from randomised controlled trials or non-randomised
controlled trials using either statistical adjustment or
matching to address baseline differences.
▸ Since having patient-speciﬁc data on both costs and
outcomes is an advantage for internal validity,
44
resource use must be a measured outcome of the
study. Modelling studies utilise the results of other
published studies, therefore, are exempt from this
criterion.
▸ Because uncertainty in an economic evaluation
comes not just from sample variation, but also from
assumptions made,
45 a sensitivity analysis is required.
Because the prices used to value resources are highly
location-speciﬁc and setting-speciﬁc,
39 46 we also note,
for the articles meeting the above criteria, the presence
of a study reporting criterion essential for the transfer-
ability of study results (usually via modelling):
39 40 separ-
ate reporting of unit costs from resource use for
economic evaluations alongside trials, or from model
parameters (eg, transition probabilities) for economic
evaluations using models.
Other data extracted for the economic evaluations
which meet the ﬁve study-quality criteria are: treatment
and study duration, primary clinical and economic
outcome measures, the setting in which treatment took
place, study design and sample size, the type (table 1)
and perspective (ie, the point of view used to deﬁne
costs) of the economic analysis, and incremental cost-
effectiveness of the CIM alternative compared to
usual care. Incremental cost-effectiveness is reported in
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converting the study currency to US$ using the Federal
Reserve annual exchange rate
47 for the study’s currency
year and then inﬂated to 2011 values using the medical
care component of the Consumer Price Index.
48
Finally, up to three additional quality measures are
included for each of these studies. The Tufts CEA
Registry
49 quality score is recorded when it was available
(note it is only available for cost-utility analyses, CUAs).
A Jadad score
50 with minor modiﬁcations (the two pos-
sible points for blinding were replaced with one point
for the use of a blinded assessor)
51 was calculated for
the economic evaluations that included a randomised
trial. The percentage of the applicable items from the
35-item BMJ checklist that were met by each article is
also reported.
41
RESULTS
As shown in ﬁgure 1, the database search identiﬁed 270
published economic evaluations. An additional 68 arti-
cles were added through the bibliography and expert-
Figure 1 The flow of records
and articles through the
systematic review.
Table 1 Types of full economic evaluations
Cost-benefit analysis Cost-effectiveness analysis (CEA)
Cost-utility analysis
(a special case of CEA)
Unit of health outcome Monetary units (eg, US$) Natural units (eg, life-years gained) Units of overall impact on length
and quality of life (eg, QALY)
Results Net benefits Incremental cost-effectiveness ratio* Incremental cost-utility ratio*
(B1−B2)−(C1−C2−S1+S2)( C 1−C2−S1+S2)/(E1−E2)( C 1−C2−S1+S2)/(QALY1−QALY2)
*Ratios are calculated when both the costs and the effects (health improvements) of one therapy alternative are higher than those of another.
When the costs are lower and the effects are better for one therapy, it is said to dominate the alternative (and the alternative is said to be
dominated) and no ratio is presented. B1, monetary value of health outcomes of alternative 1; B2, monetary value of health outcomes of
alternative 2; C1, total input costs of alternative 1; C2, total input costs of alternative 2; S1, total cost savings (economic outcomes) for
alternative 1; S2, total cost savings (economic outcomes) for alternative 2; E1, health effects of alternative 1; E2, health effects of alternative 2;
QALY1, quality-adjusted life-years of alternative 1; QALY2, quality-adjusted life-years of alternative 2.
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tions of CIM. Of these, 204 (60%) were published from
2001 through 2010 (114 full and 90 partial economic
evaluations). Of the recent full economic evaluations
almost all (103, 90%) examined the effect of one CIM
therapy and most of the balance (10, 9%) examined the
effect of two or more CIM therapies provided by the
same practitioner. Only one looked at the effect of mul-
tiple CIM therapies provided by different CIM provi-
ders.
52 CIM was generally evaluated as an adjunct to
usual care.
As shown in table 2, the 204 economic evaluations pub-
lished in the past 10 years are spread across a wide range
of CIM therapies applied to a number of different study
populations. The biggest concentration of full economic
evaluations (19 in number) pertained to the use of
NCCAM’sd e ﬁnition of manipulative and body-based prac-
tices (eg, chiropractic, osteopathic manipulation, massage,
etc) for the treatment of back pain.
53–72 However, even
this subgroup is fairly heterogeneous in terms of the
therapy (or therapies) tested and/or the type of back pain
treated. Eight of these comparisons involved chiropractic
care for back pain; one for chronic,
53 one for acute
57and
six for either type.
59 60 63 64 67 68 Five evaluated spinal
manipulation and manual therapy provided by phy-
siotherapists for chronic back pain (one),
65 acute back
pain (two)
58 69 or either (two).
56 68 Four involved osteo-
pathic manipulation; one for chronic
71 and one for sub-
acute back pain
72 and two for musculoskeletal conditions
including back pain.
66 68 Three evaluated massage; two for
chronic
55 62 and one for acute back pain.
57 The last two
studies evaluated a musculoskeletal physician (treatment
‘with a combination of manual therapy, injections, acu-
puncture and other pain management techniques’)f o r
orthopaedic referrals;
54 and a Finnish folk medicine prac-
tice called ‘bone setting’ for the treatment of patients with
chronic back pain.
61
Table 3 shows the results of the application of the
35-item BMJ checklist to the full economic evaluations
published 2001–2010.
41 On average, the number of
Table 2 Types of individual complementary and integrative medicine (CIM) therapies studied for various conditions and in
various populations: 2001–2010 (reported as the ratio of the total number of economic evaluations to the number of full
economic evaluations)
Manipulative
and
body-based
practices Acupuncture
Natural
products
Other
mind-body
medicine Homeopathy
CIM in
general
Other CIM
therapies* Totals†
Back pain 28: 19 11 :10 2:2 – 1:1 3:0 2:2 42:29
Rheumatic
disorders
9:5 6:4 6:6 2:2 – 1:0 4: 3 27 :19
Mixed populations 4:1 6:1 2:1 3:1 9:5 2:1 3: 2 24 :9
Cardiovascular
disease and
diabetes
– 1:0 8:6 6:4 1:1 – 3:1 18:12
Infection (various) ––6:4 – 7:4 –– 13 :8
Surgery 1:1 2:2 4:3 5:4 –– – 12 :10
Members of
insurance plans
3:0 2:0 –– 1:0 7:0 – 12 :0
Mental disorders
(various)
– 2:2 – 5:3 1:1 1:0 2:0 11:6
Older populations ––6:3 2:0 –– 3:1 11:4
Headaches 1:0 3:3 – 4:3 1:1 –– 9:7
Children (various
conditions)
1:0 –– – 6:4 1:0 1:0 9:4
Cancer 2:1 2:1 1:1 2:2 – 2:0 – 8:4
Pregnancy and
women’s health
– 5:5 1:0 1:0 –– – 7:5
Allergies – 1:1 –– 3:1 – 1:1 5:3
Other conditions‡ 1:1 1:1 3:3 5:4 2:1 2:0 6:2 19:11
Totals† 45: 25 41 :29 38: 28 27: 16 24:13 18: 1 25:12 204: 114
*Other CIM therapies included aromatherapy, healing touch, Tai Chi, Alexander technique, spa therapy, music therapy, electrodermal
screening, clinical holistic medicine, naturopathic medicine, anthroposophic medicine, water-only fasting, Ornish Program for Reversing Heart
Disease, use of a corset and use of a traditional mental health practitioner.
†Totals across (down) columns will not add to numbers in the totals column (row) due to individual studies addressing more than one CIM
therapy (patients in more than one group).
‡Other conditions studied included patients with multiple chemical sensitivities, respiratory disease, pharyngeal dysphagia, dyspepsia,
functional bowel disorders, other functional disorders, venous leg ulcers, major burns and constipation; patients who rated themselves as
physically ill or having low quality of life; patients in home hospice or with home nursing; long-term care workers and prisoners.
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stant during this period. However, the application of two
key items (ie, the proper use of discounting and the
inclusion of sensitivity analysis) and the disclosure of
funding sources improved signiﬁcantly, and reporting of
the study time horizon worsened signiﬁcantly. As
expected, the average overall and individual-item per-
centages were higher for the higher-quality articles
(those meeting the ﬁve study-quality criteria) and for
CUAs of CIM. It is not surprising that CUA’s quality is
higher. They generally involve more effort than other
CEAs and are required or recommended by various
national guidelines.
42 73–75 Nevertheless, it seems as
though the quality of CUAs of CIM is generally compar-
able to, or slightly better than, that seen in CUAs across
all medicine, at least in terms of the Tufts quality score,
disclosure of funding sources and the ﬁve items where
comparable data are available.
76 77
The number of full evaluations meeting each of the
ﬁve study-quality criteria are: comparison to usual care
97 (85%), all costs from a recognised perspective
96 (84%), health outcomes from a randomised or matched-
control trial 86 (75%), patient-speciﬁc data on costs and
outcomes 105 (92%) and sensitivity analyses 37 (32%).
Sixty-two (54%) of full evaluations met the ﬁrst four of
these and 31 (27%) met all ﬁve. A summary of the
results of these 31 higher-quality articles (covering 28
different studies) is shown in table 4.
54 60 62 68 71 78–103
Twenty-two of these articles (19 of the studies) reported
resource use (trials) or model parameters (models) sep-
arate from unit prices—a minimum measure of study
transferability.
54 62 68 71 78 80–85 87–93 95 100 101 103 For
those studies which included a randomised trial, the
modiﬁed Jadad scores ranged from 2 to 4 on a scale
from 0 to 4. The Tufts CEA Registry quality scores for
the studies containing a CUA ranged from 4 to 6.5 on a
scale from 1 to 7. The percentage of the applicable
items on the BMJ checklist met by these studies ranged
from 66% to 97%.
Of the 56 comparisons made in these studies, 16 (29%)
are cost saving—that is, the added CIM therapy had
better health outcomes and lower costs than usual
care alone. Cost savings were seen for acupuncture
alone (instructional visits with an acupuncturist followed
by home self-care by the partner for pregnant women
with breech presentations at 33 weeks in terms of reduc-
tions in both breech presentation at birth and ceasar-
eans in the Netherlands,
91 and treatment by traditional
Chinese medicine-trained licensed acupuncturists in
private acupuncture clinics in the UK for low-back pain
in terms of quality-adjusted life-years or QALYs from the
societal perspective
85) and in combination with other
therapies (along with manual therapy, injections and
other pain management for patients referred to an
Table 3 Comparison of various quality measures between economic evaluations of complementary and integrative medicine
(CIM) and conventional medicine
Economic evaluations of CIM
Cost-utility analyses
(CUAs) across all
medicine†
All full 2001–2005 2006–2010
Higher
quality CUAs 1998–2001 2002–2005
n=114 n=59 n=55 n=31 n=27 n=300 n=637
Average percentage met of applicable items on
BMJ checklist
72 71 73 87 89
Presented the study perspective clearly (%) 61 58 64 87 93** 74 83**
Presented the study time horizon (%) 96 98* 93* 100 100* 75 87*
Conducted and reported sensitivity analysis (%) 32 22** 44** 100 93** 93 84**
Discounted costs and health effects, where
appropriate (%)§
60 25* 76* 94 100* 85 84*
Stated year of currency for resource costs (%) 59 54 60 77 78** 83 85**
Separate reporting of resource use (trials),
parameters (models) and unit costs
(for transferability)
52 51 53 71 70
Disclosed funding sources (%) 72 58* 76* 84 93* 65‡*
Industry sponsored (%) 10 12 11 10 7 18‡
Average Tufts quality score (CUAs only) 4.75*** 4.25‡***
*χ
2 Test p value<0.001.
**χ
2 Test p value<0.01.
***t Test p value=0.002; comparisons were made between CIM economic evaluations published 2001–2005 and those published 2006–2010,
and between CUAs of CIM 2001–2010 and CUAs of all medicine 2002–2005.
†Data from table 3 in Neumann.
77
‡Data from table 3 in Neumann et al.
76 Industry sponsored was calculated as a percent all studies 1976–2001.
§Denominators for the percentages reported in this row are the number of studies which evaluated impacts past 1 year in either the base
case or in sensitivity analyses. For the first five columns the denominators are 25, 8, 17, 16 and 11, respectively. This information was not
available for the last two columns.
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Economics of complementary and integrative medicineTable 4 Summary of results of complementary and integrative medicine (CIM) economic evaluations that met five study-quality criteria (31 articles representing 28 studies)
CIM therapy
compared to
usual care
alone*
Treatment
duration/
study
duration
Patient
population Primary outcome(s)
Setting (information
often limited by what
was reported)
Sample
size
Study
design and
quality
scores†
Resource
use (trials),
parameters
(models),
and unit
costs (both)
reported
separately?
Form and
perspective
of economic
evaluation
Incremental
cost-effectiveness
ratio (2011 US$)‡
Acupuncture studies
Brown
et al
54
Adjunctive
acupuncture,
manual therapy,
injections and
other pain
management
Up to 1 year/
1 year
Patients referred
for an orthopaedic
outpatient
consultation who
were classified as
unlikely to require
surgery
Clinical: SF-36 and,
if appropriate,
Aberdeen Low Back
Pain Scale or
Edinburgh Knee
Function Scale;
economic: EQ5D
Individualised care
from one ’physical
medicine’ physician in
a hospital outpatient
clinic in Scotland
829 R (2) 81% Yes CEA-H Cost saving
BMJ CUA-H Cost saving
van den
Berg et al
91
Adjunctive breech
version acumoxa
2 visits/from
33 weeks to
delivery
Pregnant women
with breech
presentation at
33 weeks
Economic:
percentage of breech
presentations at
delivery—two ‘main
analyses’—with and
without the option of
external cephalic
versions
2 instructional visits to
an acupuncturist
followed by daily home
self-care, the
Netherlands
NA Decision tree
model
Yes CEA-P Cost savings
81% BMJ CEA-P Cost savings
Ratcliffe
et al
85 and
Thomas
et al
89
Adjunctive
acupuncture
3 months/
2 years
Patients with
low-back pain
Clinical: bodily pain
fm SF-36; economic:
QALYs fm SF-6D
Up to 10 treatments
from a TCM-trained
acupuncturist in
acupuncture clinic in
the UK
239 R (3) Yes CUA-S Cost saving
Tufts 5 CUA-P US$8755/QALY
94%/94%
BMJ
Kim et al
81 Adjunctive
acupuncture
10
treatments in
3-month
cycles/
5 years
60-year-old women
with first time acute
low-back pain
Clinical:
Roland-Morris
Disability, symptom
bothersomeness;
economic: QALYs fm
literature
Hospital-based
licensed oriental
medical doctors in
South Korea
NA Markov
model
Yes CUA-S US$3086/QALY
Tufts 4.5
94% BMJ
Witt et al
97 Adjunctive
acupuncture
3 months/
6 months
Patients with
dysmenorrhoea
Clinical: pain
intensity VAS;
economic: QALYs fm
SF-6D
Up to 15 sessions with
a physician trained in
acupuncture
(A-diploma) in
Germany
201 R (3) No CUA-S US$4708/QALY§
Tufts 5.5
77% BMJ
Witt et al
96 Adjunctive
acupuncture
3 months/
6 months
Patients with
chronic low-back
pain
Clinical: Hannover
Functional Ability
Questionnaire;
economic: QALYs fm
SF-6D
Up to 15 sessions with
a physician trained in
acupuncture
(A-diploma) in
Germany
2518 R (3) No CUA-S US$16230/QALY§
Tufts 4.5
73% BMJ
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Incremental
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Witt et al
99 Adjunctive
acupuncture
Up to 15
treatments/
3 months
Patients with
headache
Economic: QALYs
fm SF-6D
10–15 sessions with
physician trained in
acupuncture
(A-diploma) in
Germany
3182 R (2) No CUA-S US$18225/QALY§
Tufts 5.5
88% BMJ
Willich
et al
94
Adjunctive
acupuncture
Up to 15
treatments/
3 months
Patients with
chronic neck pain
Clinical: Neck Pain
and Disability Scale;
economic: QALYs fm
SF-6D
10–15 sessions with
physician trained in
acupuncture
(A-diploma) in
Germany
3451 R (2) No CUA-S US$19226/QALY§
Tufts 5
88% BMJ
Wonderling
et al
100 and
Vickers
et al
93
Adjunctive
acupuncture
3 months/
1 year
Patients with
chronic headache
Clinical: headache
severity score;
economic: QALYs fm
SF-6D
Acupuncture-trained
physiotherapists in
own clinics in the UK
401 R (3) Yes CUA-S US$19785/QALY
Tufts 5 CUA-P US$21074/QALY
97%/93%
BMJ
Reinhold
et al
86
Adjunctive
acupuncture
3 months/
3 months
Patients with
chronic hip or knee
osteoarthritis
Economic: QALYs
fm SF-6D
10–15 sessions with
physician trained in
acupuncture
(A-diploma), Germany
489 R (3) No CUA-S US$27900/QALY§
Tufts 4
87% BMJ
Witt et al
98 Adjunctive
acupuncture
Up to 15
treatments/
3 months
Patients with
allergic rhinitis
Economic: QALYs
fm SF-6D
10–15 sessions with
physician trained in
acupuncture
(A-diploma) in
Germany
981 R (3) No CUA-S US$28137/QALY§
Tufts 4
94% BMJ
Manipulative and body-based practices—see also Brown et al
Korthals-de
Bos et al
82
Manual therapy 6 weeks/
1 year
Patients with neck
pain
Clinical: perceived
recovery, pain VAS,
and Neck Disability
Index; economic: All
clinical plus QALYs
fm EQ-5D
Up to 6 weekly 45 min
sessions with a
physiotherapist who is
also a registered
manual therapist in the
Netherlands
183 R (3) Yes CEA-S Cost saving
Tufts 6.5 CEA-S Cost saving
83% BMJ CEA-S Cost saving
CUA-S Cost saving
Williams
et al
71
Adjunctive
osteopathic spinal
manipulation
2 months/
6 months
Patients with
subacute (2–
12 week) back
pain
Clinical: Extended
Aberdeen Spine
Pain Scale;
economic: QALYs fm
EQ-5D
3 or 4 sessions with a
general practitioner
who is a registered
osteopath at own clinic
in UK
187 R (3) Yes CUA-P US$8730/QALY
Tufts 5
89% BMJ
UK BEAM
Trial
Team
68
Adjunctive spinal
manipulation and
exercise
3 months/
1 year
Patients with
low-back pain
Economic: QALYs
fm EQ-5D
8 sessions with a
chiropractor,
osteopath, or
physiotherapist at a
private or NHS site in
the UK
1287 R (3) Yes CUA-P US$8425/QALY
Adjunctive spinal
manipulation
Tufts 6 CUA-P US$10642/QALY
93% BMJ
Continued
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cost-effectiveness
ratio (2011 US$)‡
Hollinghurst
et al
62
Alexander
technique
6 lessons/
1 year
Patients with
chronic or
recurrent
non-specific back
pain
Clinical:
Roland-Morris
Disability
Questionnaire
(RMDQ); economic:
above plus QALYs
fm EQ-5D
Alexander technique
teachers and massage
therapists at own
locations in the UK
579 R (3) Yes CUA-P US$13300/QALY
CEA-P US$255/RMDQ pt
Alexander
technique plus
exercise¶
6 lessons/
1 year
Tufts 5.5 CUA-P US$12022/QALY
CEA-P US$144/RMDQ pt
Massage 6 sessions/
1 year
97% BMJ CUA-P Dominated
CEA-P US$1010/RMDQ pt
Massage plus
exercise¶
6 sessions/
1 year
CUA-P US$11959/QALY
CEA-P US$354/RMDQ pt
Haas
et al
60
Treatment in a
chiropractic clinic
Unspecified/
1 year
Patients with acute
low-back pain
Clinical and
economic: pain
severity 100 mm
VAS and revised
Oswestry Disability
Questionnaire
Doctors of Chiropractic
in own clinics in
Oregon, the USA
1943 MC No CEA-P US$21/pain mm
Patients with
chronic low-back
pain
837 66% BMJ CEA-P US$0.73/pain mm
Natural products
Braga
et al
102
Adjunctive
preoperative
arginine and ω-3
fatty acid
supplementation
5d a y s /
5 days plus
hospital stay
Patients with
gastrointestinal
cancer undergoing
surgery
Economic:
percentage of
patients without
complications
12.5 g arginine, 3.3 g
ω-3 fatty acids and
1.2 g RNA in liquid
daily taken orally for
5 days before surgery,
Italy
204 R (3) No CEA-H Cost saving
88% BMJ
Stevenson
et al
103 and
Stevenson
et al
88
Vitamin K1 10 years/
10 years
Postmenopausal
women with
osteoporosis/
osteopenia
Clinical: osteoporotic
fracture; economic:
QALYs fm the
literature
10 mg/day of vitamin
K1 daily, the UK
NA Patient-level
simulation
model
Yes CUA-P Cost saving
Tufts 4.5
81%/84%
BMJ
Trevithick
et al
90
Adjunctive
antioxidants
(vitamins C and E
and β-carotene)
25 years/
25 years
Cohort of Ontario
residents aged 50–
54 (prevention of
cataracts)
Clinical: cataract
formation
750 mg/day vitamin C,
600 mg/day vitamin E
and 18 mg/day
β-carotene daily,
Canada
NA Markov-type
cohort model
Yes CEA-P Cost saving
79% BMJ
Schmier
et al
87
Adjunctive ω-3
fatty acid
supplementation
42 months/
42 months
Males with a
history of a heart
attack
Economic: fatal MIs
and cardiovascular
deaths
‘Fish oil pills’, the USA NA Decision
analytic
model
Yes CEA-S Cost saving
77% BMJ CEA-P US$11903/fatal MI
avoided
Continued
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Lamotte
et al
83
Adjunctive ω-3
polyunsaturated
fatty acids
3.5 years/
lifetime
Patients after an
acute myocardial
infarction
Economic: life-years
saved
∼465 mg EPA and
∼385 mg DHA ethyl
esters in a daily
gelcap, Australia,
Belgium, Canada,
Germany and Poland
NA Decision tree
model
Yes CEA –P US$5413/LYG
Australia
89% BMJ CEA –P US$8184/LYG
Belgium
CEA –P US$4476/LYG
Canada
CEA –P US$6750/LYG
Germany
CEA –P US$7747/LYG
Poland
Quilici
et al
84
Adjunctive ω-3
polyunsaturated
fatty acids
4 years/
lifetime
Patients after an
acute myocardial
infarction
Economic: life-years
gained (LYG),
QALYs fm the
literature, deaths
avoided
∼465 mg EPA and
∼385 mg DHA ethyl
esters in a daily
gelcap, the UK
NA Markov
model
Yes CEA –P US$28420/LYG
Tufts 5 CUA-P US$35940/QALY
93% BMJ
Franzosi
et al
79
Adjunctive ω-3
polyunsaturated
fatty acids
3.5 years/
3.5 years
Patients with
recent myocardial
infarction
Clinical: death and
non-fatal MI or
stroke; economic:
LYG
∼465 mg EPA and
∼385 mg DHA ethyl
esters in a daily
gelcap, Italy
5664 R (4) No CEA-P US$41867/LYG
85% BMJ
Black
et al
78
Adjunctive
glucosamine
sulphate
22.6 years/
22.6 years
Patients with
osteoarthritis of the
knee
Clinical: pain,
function, joint space
loss; economic:
QALYs fm the
literature
Glucosamine sulphate
powder 1500 mg daily
in oral solution, the UK
NA Cohort
simulation
model
Yes CUA-P US$59053/QALY
84% BMJ
Other complementary and integrative medicine therapies
Wilson and
Datta
95
Adjunctive
yang-style tai chi
1 year/1 year Nursing home
residents at
average risk for a
fall
Economic: hip
fractures avoided
2 classes/week
monitored by a
certified tai chi
instructor and an
assistant, the USA
NA Decision tree
model
Yes CEA-P Cost saving
96% BMJ
Herman
et al
80
Adjunctive
naturopathic care
including
acupuncture,
relaxation
exercises, dietary
and exercise
advice
3 months/
6 months
Patients with
chronic low-back
pain
Clinical: Oswestry
Disability
Questionnaire;
economic: QALYs fm
SF-6D
Twice weekly visits to
licensed naturopathic
doctors also trained in
acupuncture in a
worksite clinic in
Canada
70 R (3) Yes CUA-S Cost saving
Tufts 5 CEA-E US$191/absentee
day avoided
96% BMJ CBA-E Cost saving
Continued
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Van
Tubergen
et al
92
Combined
spa-exercise
therapy
3 weeks/
40 weeks
Patients with
ankylosing
spondylitis
Clinical: Bath
Ankylosing
Spondylitis
Functional Index
(BASFI 10pts), pain
VAS, well-being VAS
and morning
stiffness in minutes;
economic: above
plus QALYs fm
EQ-5D
3-week stay at one of
two spa-resorts with
therapy provided by
trained
physiotherapists, the
Netherlands
120 R (3) Yes CEA-S US$2159/BASFI pt
(spa in Austria)
Tufts 4.5 CEA-S US$4215/BASFI pt
(spa in the
Netherlands)
90% BMJ CUA-S US$12703/QALY
(spa in Austria)
CUA-S US$31609/QALY
(spa in the
Netherlands)
Zijlstra
et al
101
Adjunctive spa
therapy
2.5 weeks/
1 year
Patients with
fibromyalgia
Economic: QALYs
fm VAS and SF-6D
18-day stay at a spa in
Tunisia with a variety
of treatments, the
Netherlands
128 R (3) Yes CUA-S US$46443/QALY
(VAS)
Tufts 4 CUA-S US$92886/QALY
(SF-6D)
97% BMJ
*The use of the term ‘adjunctive’ in this column indicates complementary and alternative medicine (CAM) therapies used in addition to usual care for that condition unless otherwise indicated.
†Study design: R, randomised; MC, matched controls and/or results statistically adjusted for baseline differences. A modified Jadad score (maximum score = 4) is provided if the study was
randomised. If the study was a CUA and a quality score was available from the Tufts Medical Center Institute for Clinical Research and Health Policy Studies CEA Registry (https://research.
tufts-nemc.org/cear/Default.aspx), it is reported. Quality scores range from 1 to 7 with 7 representing the highest quality. The last number is the percent of the applicable items on the BMJ
35-item quality checklist that this study met. If a study had more than one publication, both percentages were reported. The BMJ checklist is found in Drummond et al.
41
‡The costs reported in each study were first converted to US$ using the Federal Reserve annual exchange rate (http://www.federalreserve.gov/releases/g5a/20090102/, accessed 30 Jan 2012)
for the study’s currency year and then inflated to 2011 values using the medical care component of the Consumer Price Index (http://www.bls.gov/cpi/cpi_dr.htm#2007, accessed 30 Jan 2012).
In comparisons labelled as cost saving the CIM therapy both improved health and lowered costs compared to usual care. In the comparison labelled dominated the CIM therapy had worse
health outcomes and higher costs than usual care.
§These studies did not report a currency year so it was estimated as being 1 year prior to publication.
¶Compared to usual care plus exercise.
CBA, cost-benefit analysis; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; DHA, Docosahexaenoic acid; E, employer perspective; EPA, Eicosapentaenoic acid; H, hospital
perspective; MI, myocardial infarction; P, payer perspective; QALY, quality-adjusted life-year; S, societal perspective; VAS, visual analogue scale.
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eorthopaedic surgeon’so f ﬁce in Scotland who were
unlikely to need surgery in terms of both improvements
in health-related quality of life and QALYs
54). Cost
savings were also seen for manual therapy delivered by a
physiotherapist, who is also a registered manual therapist,
for neck pain in terms of perceived recovery, pain, neck
disability and QALYs
82; for preoperative oral supplemen-
tation with arginine and ω-3 fatty acids for patients with
gastrointestinal cancer undergoing surgery
102; for
vitamin K1 supplementation for postmenopausal women
with osteopenia and osteoporosis in terms of QALYs
103;
for supplementation with vitamins C and E and
β-carotene for cataract prevention
90; for ﬁsh oil supple-
mentation in men with a history of heart attack
87; for tai
chi to prevent hip fractures in nursing home residents
95
and for naturopathic care offered through a worksite
clinic for chronic low-back pain in terms of both reduc-
tions in absenteeism and gains in QALYs.
80
Of the 28 cost-utility comparisons, one (massage for
low-back pain
62) was dominated— that is, had worse
health outcomes and higher costs than usual care.
Five (18%) are cost saving,
54 80 82 85 103 5 (18%) have
incremental cost-effectiveness ratios (ICERs) between
US$0 and US$10 000 per quality-adjusted life-year
(QALY),
68 71 81 85 97 and 89% had ICERs less than
US$50 000/QALY, a threshold often considered to repre-
sent the upper limit of society’s value for a QALY.
104 The
cost-saving cost-utility studies were included in the para-
graph above (ie, those that mention QALYs). The
studies with cost-utility ICERs between US$0 and
US$10 000 per QALY were: treatment by traditional
Chinese medicine-trained licensed acupuncturists in
private acupuncture clinics in the UK for low-back
pain.
85 hospital-based acupuncture by licensed oriental
medical doctors in South Korea for 60-year-old women
with ﬁrst-time acute low-back pain,
81 acupuncture from
physicians with at least 140 h of training (A-diploma) in
Germany for patients with dysmenorrhoea,
97 osteopathic
spinal manipulation by a general practitioner who is a
registered osteopath in the UK for patients with sub-
acute back pain,
71 and an exercise programme plus
spinal manipulation from a chiropractor, osteopath or
physiotherapist at a private or National Health Service
(NHS) site in the UK for low-back pain.
68 The average
percentage of applicable BMJ checklist items met by
each study was slightly lower for those studies with at
least one cost-saving comparison (85% vs 88%), but the
difference was not statistically signiﬁcant (t test=0.75, p
value=0.460).
DISCUSSION
This comprehensive systematic review identiﬁed 338 eco-
nomic evaluations of CIM; 204 of which were published
recently (2001–2010) covering a wide range of CIM ther-
apies for a variety of populations. Although most patients
who use CIM use more than one modality
35 and despite
the attention given to integrative medicine (coordinated
access to conventional medicine and CIM),
105 this system-
atic review found only one study that examined the
effects of use of multiple CIM practitioners.
52 In general,
the quality of the recent full economic evaluations has
held constant and is in line with what is seen in economic
evaluations in conventional medicine. Details of the 31
recent higher-quality full economic evaluations indicate
potential cost-effectiveness and cost savings across a
variety of CIM therapies applied to different conditions.
Owing to the non-generalisable nature of economic eva-
luations, the cost estimates shown are speciﬁc to their
study settings.
40 However, 22 articles provided at least
the minimum information for study transferability.
Therefore, their results could be adapted via modelling
to determine the economic impact of these interventions
in other settings.
The strengths of this study are the comprehensive
search strategy, which revealed a substantial number of
published economic evaluations of CIM, the use of two
reviewers and the use of multiple measures of study
quality. Higher-quality studies were identiﬁed and high-
lighted for policy makers using a simple objective list of
quality criteria, which reduced the potential for bias.
The weaknesses of this study are similar to those of the
other systematic reviews. The reviewers were not blinded
to journals and article authors, which may have inﬂu-
enced results. Also, some aspects of what makes a quality
economic evaluation could not be judged from what was
reported. For example, ideally, pragmatic trials enrol
patients typical of normal caseload in typical settings
with typically trained and experienced practitioners fol-
lowing them under routine conditions (ref.
37, p. 251).
Judgements as to whether these criteria were met were
not always possible from the reports, and were beyond
the scope of this review. Finally, publication bias was not
assessed. However, since the major goal of this study was
to establish the extent of the published literature on this
topic and to highlight the results of the higher-quality
studies, it is not clear that publication bias is relevant
here.
The number of economic evaluations of CIM found
and reviewed by this study far exceeds the numbers
found in previous studies.
11 19–21 23 This study found a
total of 338 economic evaluations of CIM published
between and including 1979 and 2010; 211 of these were
full economic evaluations. White and Ernst
19 identiﬁed
34 economic evaluations of CAM published 1987–1999;
11 of which were full economic evaluations. Between
1999 and October 2004, Herman et al
20 identiﬁed 56 eco-
nomic evaluations of CAM (39 full evaluations). Between
1994 and May 2004 Hulme and Long
21 identiﬁed 19 full
economic evaluations of CAM, and over a similar period
(1995–2007) Doran et al
23 found 43 economic evalua-
tions (15 full evaluations). Maxion-Bergemann et al
11
identiﬁed 5 (1 full) economic evaluations over an
unspeciﬁed search period. The large number of eco-
nomic evaluations found in this study reﬂects the facts
that: (1) all evaluations from previous reviews were
12 Herman PM, Poindexter BL, Witt CM, et al. BMJ Open 2012;2:e001046. doi:10.1136/bmjopen-2012-001046
Economics of complementary and integrative medicineincluded; (2) a number of studies have been published
since the last search dates of prior reviews and (3) a more
extensive search strategy was used. It should be noted
that 20% of the articles (68 of 338) in this review were
identiﬁed through bibliography searches and from
expert lists. Therefore, even the application of a long list
of search terms to multiple databases does not guarantee
that all CIM studies will be identiﬁed. However, there is
some evidence that the indexing of these articles in
medical databases is improving; studies from bibliograph-
ies and expert lists made up 32% of found articles pub-
lished 2000 and before, but only 12% recent articles.
There are several implications of this study for policy
makers, clinicians and future researchers. First, there is
a large and growing literature of quality economic eva-
luations in CIM. However, although indexing is improv-
ing in databases, ﬁnding these studies can require going
beyond simple CIM-related search terms. Second, the
results of the higher-quality studies indicate a number of
highly cost-effective, and even cost saving, CIM therap-
ies. Almost 30% of the 56 cost-effectiveness, cost-utility
and cost-beneﬁt comparisons shown in table 4 (18% of
the CUA comparisons) were cost saving. Compare this
to 9% of 1433 CUA comparisons found to be cost saving
in a large review of economic evaluations across all
medicine.
106 Third, by meeting the ﬁve study-quality cri-
teria, the studies shown in table 4 can each be consid-
ered a reasonable indicator of the health and economic
impacts of the CIM therapy studied, at least in that popu-
lation and setting. These studies, especially those showing
cost savings, should be considered further for applicabil-
ity in other settings. This requires the study to be transfer-
able.
39 Fortunately, the majority of the higher-quality
studies met our measure of study transferability—
resource use or model parameters, and unit costs were
reported separately.
Given the substantial number of economic evaluations
of CIM found in this comprehensive review, even
though it can always be said that more studies are needed,
what is actually needed are better-quality studies—both
in terms of better study quality (to increase the validity
of the results for its targeted population and setting)
and better transferability (to increase the usefulness of
these results to other decision makers in other settings).
Therefore, the following recommendations are made.
1. That all studies measuring the effectiveness of CIM at
least consider also measuring input costs and eco-
nomic outcomes.
2. That at least one arm of the study be some version of
commonly available (usual) care, and that usual care
and all interventions studied be described in sufﬁ-
cient detail that decision makers in other settings can
determine what was done and whether the study’s
usual care comparator is applicable in their setting.
3. That consideration be given to how CIM is typically
used (eg, multiple CIM therapies) or can be used
(eg, coordinated integrative care models) when
designing studies.
4. That changes in resource use be reported separately
from unit costs in economic evaluations alongside
clinical trials and that model parameters and unit
costs be clearly reported in decision-analytic model-
ling studies.
5. That all economic evaluations contain sensitivity ana-
lyses to increase the reliability of results.
6. That more consideration be given to modelling as a
method to estimate economic outcomes for existing
effectiveness trial results, and to generalise existing
quality economic evaluation results to other
jurisdictions.
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